Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
300 participants
OBSERVATIONAL
2007-04-30
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genetic Analysis of PHACE Syndrome (Hemangioma With Other Congenital Anomalies)
NCT01016756
Studies of Hereditary Hemorrhagic Telangiectasia
NCT00004648
Genetic Study of Brain Tumors in Young Children
NCT00010101
Identification of Genetic and Cellular Markers Associated With Vascular Endothelial Modifications in Cutaneous Arteriovenous Malformations
NCT01774916
Genetics of Arteriovenous Malformations
NCT02445430
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Buccal smear (cheek cells) or small blood sample (4 mL or 1 teaspoon) from child being seen in the Dermatology clinic having infantile hemangioma or vascular anomaly
* Buccal smear (cheek cells) or small blood sample (4 mL or 1 teaspoon) from parents of child
If you and your child agree to be in this study, the following will happen:
1. Informed consent and permission to use or disclose your/your child's health information for research purposes will be obtained by Dr. Drolet, the principal investigator, or her research team. You will receive a copy of this consent form.
2. A buccal swab or blood sample will be obtained from you and your child; buccal sampling involves rubbing the inside of your cheek and removing cells to perform a genetic test called "Genomewide Association (GWA).
We expect you and your child to be involved in this study until you and your child have the genetic testing performed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
FAMILY_BASED
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Patients with a hemangioma.
Cheek cell samples or blood sample (4mL)
DNA will be extracted from cheek cell or blood samples from parents and child having hemangioma.
B.
Patients with a vascular anomaly.
Cheek cell sample or blood sample (4mL)
DNA will be extracted from cheek cell or blood samples of parents and child with a vascular anomaly.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cheek cell samples or blood sample (4mL)
DNA will be extracted from cheek cell or blood samples from parents and child having hemangioma.
Cheek cell sample or blood sample (4mL)
DNA will be extracted from cheek cell or blood samples of parents and child with a vascular anomaly.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of infantile hemangioma and/or vascular anomaly
* Unaffected twin sibling
* Each patient's authorized legal guardian must understand the nature of the study and must provide written informed consent. Each patient must also give assent to study participation.
Exclusion Criteria
* If the lesion has resolved and cannot be confirmed as a hemangioma by clinical exam
* If the biologic parents are unwilling or unable to submit DNA samples the child will be excluded from the DNA study. Therefore, if DNA samples cannot be or are not obtained from both biologic parents, the child and family will be excluded from the study.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Children's Hospital and Health System Foundation, Wisconsin
OTHER
Medical College of Wisconsin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Beth A Drolet, MD
Professor and Vice Chairman of Pediatric Dermatology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Beth Drolet, MD
Role: PRINCIPAL_INVESTIGATOR
Medical College of Wisconsin
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Genetics of Hemangioma
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.